Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

DelveInsight's, “Hereditary Angioedema Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hereditary Angioedema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hereditary Angioedema Pipeline. Dive into DelveInsight's comprehensive report today! @ Hereditary Angioedema Pipeline Outlook

Key Takeaways from the Hereditary Angioedema Pipeline Report

• On 19 August 2025, CSL Behring announced a phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC).
• DelveInsight's Hereditary Angioedema pipeline report depicts a robust space with 20+ active players working to develop 30+ pipeline therapies for Hereditary Angioedema treatment.
• The leading Hereditary Angioedema Companies such as Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
• Promising Hereditary Angioedema Pipeline Therapies such as NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.

Stay ahead with the most recent pipeline outlook for Hereditary Angioedema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hereditary Angioedema Treatment Drugs

Hereditary Angioedema Emerging Drugs Profile

• KVD900: KalVista Pharmaceuticals

KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020 the drug is in Phase III stage of development for the treatment of Hereditary angioedema.

• PHA121: Pharvaris

PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase II stage of development.

• BMN 331: BioMarin Pharmaceutical

BMN 331 is a gene therapy product candidate for HAE. It is currently in Phase I stage of development.

The Hereditary Angioedema Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hereditary Angioedema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema Treatment.
• Hereditary Angioedema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hereditary Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hereditary Angioedema market

Explore groundbreaking therapies and clinical trials in the Hereditary Angioedema Pipeline. Access DelveInsight's detailed report now! @ New Hereditary Angioedema Drugs

Hereditary Angioedema Companies

Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.

Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

Hereditary Angioedema Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Unveil the future of Hereditary Angioedema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hereditary Angioedema Market Drivers and Barriers

Scope of the Hereditary Angioedema Pipeline Report

• Coverage- Global
• Hereditary Angioedema Companies- Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
• Hereditary Angioedema Pipeline Therapies- NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
• Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hereditary Angioedema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hereditary Angioedema Companies, Key Products and Unmet Needs

Table of Contents